{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-003574","form_type":"8-K","ticker":"HBIO","cik":"0001123494","company_name":"HARVARD BIOSCIENCE INC","filed_at":"2025-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.582623+00:00","generated_at":"2026-05-20T02:25:20.793364+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Harvard Bioscience appoints John Duke to board; incentive share pool increases 3.9M","bullets":["John Duke appointed to board effective June 2, 2025; will serve on audit and nominating committees.","Thomas Loewald resigned from board effective May 30, 2025; no disagreement cited.","Katherine Eade named Lead Independent Director.","Shareholders approved Amended and Restated 2021 Incentive Plan, increasing authorized shares by 3,923,000.","Non-binding advisory vote on executive compensation passed with 23.8M for vs 2.5M against."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-003574","json":"https://secwatch.observer/filing/0001171843-25-003574.json","markdown":"https://secwatch.observer/filing/0001171843-25-003574.md","text":"https://secwatch.observer/filing/0001171843-25-003574.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1123494/000117184325003574/0001171843-25-003574-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1123494/000117184325003574/f8k_060225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T02:25:20.793364+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"830d1a934c","claim":"John D. Duke was appointed as Director at HARVARD BIOSCIENCE INC.","evidence_excerpt":"On June 2, 2025, the Board appointed John D. Duke to serve as a member of the Board, June 2, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1123494/000117184325003574/0001171843-25-003574-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"8775eeed01","claim":"Thomas Loewald resigned as Director at HARVARD BIOSCIENCE INC.","evidence_excerpt":"On May 30, 2025, Thomas Loewald informed the Company of his resignation from the board of directors (the “Board”) of Harvard Bioscience, Inc. (the “Company”), effective May 30, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1123494/000117184325003574/0001171843-25-003574-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"e7ccb5d69c","claim":"Katherine Eade was appointed as Lead Independent Director at HARVARD BIOSCIENCE INC.","evidence_excerpt":"One June 2, 2025, the Board appointed Katherine Eade as the Board’s Lead Independent Director.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1123494/000117184325003574/0001171843-25-003574-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Lead Independent Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}